No Data
No Data
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Citi Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
Citi analyst David Hoang maintains $Solid Biosciences(SLDB.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 63.4% and a
Solid Biosciences' SGT-003: A Promising Leap in DMD Therapy With Cardiac Safety Superiority
Express News | Solid Biosciences Inc : Leerink Partners Raises Target Price to $28 From $12
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results